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Abstract
Background: Gliomas are one of the most common malignant brain tumors and bring a big threat to human life
as traditional therapy is unsatisfactory. RBM5 was a RNA-binding motif protein and was reported as a tumor suppressor.
But the role of RBM5 in gliomas was unknown.
Methods: The mRNA level of RBM5 was determined in gliomas tissues and cell lines by real-time quantitative
PCR (qRT-PCR) assay while the association of RBM5 expression with prognosis was analyzed by Kaplan-Meier
method and compared by log-rank test. Lentivirus was used to overexpress RBM5 in gliomas cells. MTT and
BrdU incorporation assay were used to determine cell proliferation and DNA synthesis when the ability of cell
migration and invasion was analyzed by transwell assay with/without Matrigel. Cell apoptosis rate was determined with
fluorescence-activated cell sorting (FACS) method. Then, expression of apoptosis molecules and critical members in
Wnt/β-catenin pathway were detected by western blot analysis.
Results: RBM5 was shown to be downregulated in gliomas tissues and gliomas cell lines. And decreased RBM5
expression was clinically correlated with tumor stage, patient age, and poor prognosis of gliomas patients. The
proliferation and DNA synthesis was dramatically inhibited when RBM5 was overexpressed in SHG44 or U251
cells. Also, the ability of cell migration and invasion was disrupted. Then, the level of β-catenin and Cyclin D1
significantly decreased when DKK1 and P-GSK-3β increased reversely in SHG44 cells, which suggested that
RBM5 inhibited canonical Wnt/β-catenin signaling. Meanwhile, we demonstrated that caspase3-mediated
apoptotic pathway was activated by RBM5 as Bax, TNF-α, and cleaved caspase3 were greatly upregulated
while antiapoptotic molecule Bcl-2 was downregulated. Additionally, that apoptotic rate increased significantly from
less than 1 to 32% in RBM5-overexpressed SHG44 cells further supported the pro-apoptosis role of RBM5 in gliomas
cells.
Conclusions: RBM5 plays a suppressor role in human gliomas by inhibiting Wnt/β-catenin signaling and inducing cell
apoptosis. This study improves our knowledge about the carcinogenesis and progression of human gliomas, which
would greatly contribute to the therapy for gliomas patients.
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Background
Gliomas are one of the most common malignant brain
tumors and account for about 80% of all primary malignant
central nervous system (CNS) tumors [1]. The latest statis-
tics data predict that about 23,770 new cases and 16,050
new deaths of CNS tumors would occur in 2016 in the
USA [2]. What is worse, the outcomes of patients with the
gliomas particularly with the glioblastoma were very disap-
pointing despite the great advancement in therapeutics in-
cluding surgical remove, chemotherapy, and radiation
therapy. The median survival time of patients diagnosed
with glioblastoma ranged from 12 to 15 months while the
5-year survival rate was less than 5% [3]. So, it is urgent to
develop novel therapeutics to fight against gliomas and to
improve the survival of gliomas patients.
Elucidation of molecular mechanism underpinning
tumorigenesis and progression has been a promising
way to develop novel therapeutics. For example, the
study about the critical role of VEGF during tumor
angiogenesis has directly prompted the come-out of
avastin against NSCLC [4]. The important roles of
tyrosine kinase in cell proliferation caused synthesis of
a series of tyrosine kinase inhibitors [5]. RNA-binding
motif protein 5 (RBM5), also called LUCA-15 or H37,
is a nuclear RNA-binding protein which contains two
RNA recognition motifs, two zinc fingers and a serine-
arginine-rich domain [6]. It is located at chromosomal
locus 3p21.3 which domain was reported to be the
most frequently deleted or mutated in a series of human
cancers [7]. For example, RBM5 was often genetically
deleted in lung, renal, and breast cancer [8]. Moreover,
RBM5 was evaluated as a therapeutic and diagnostic
marker in lung cancer [9]. Overexpression of RBM5
inhibited growth of human prostate cancer while it
was demonstrated to be downregulated in serous ovarian
carcinoma [10, 11]. In fact, accumulating data suggest
that RBM5 was a tumor suppressor and inhibited
tumor growth or progression by triggering apoptosis
and inducing cell cycle G1/S arrest [12]. In early re-
search, RBM5 was reported to regulate the splicing of
an apoptotic factor Fas and resensitize lung cancer
cells A549 to cisplatin [13]. Also, RBM5 was shown to
inhibit Wnt/β-catenin signaling in A549 cells [14].
Wnt/β-catenin signaling was vital to cancer cell prolif-
eration. However, there was no report about the role
of RBM5 in gliomas.
In this study, we found RBM5 was decreased in
gliomas tissue samples and clinically correlated with
poor prognosis in gliomas. To investigate the role of
RBM5 in gliomas as well as the mechanism mediated
by RBM5, a series of in vitro experiments was designed.
And we showed that RBM5 played a suppressor role in
gliomas by inhibiting canonical Wnt signaling and enhan-
cing apoptosis.
Methods
Cell lines and sample tissues
Cell lines (SHG44, U87, U251) were obtained from Cell
Bank Type Culture Collection of Chinese Academy of
Sciences (CBTCCCAS, Shanghai, China) and maintained in
DMEM (Gibco, USA) containing 10% fetal bovine serum,
100 units/mL penicillin, and 100 μg/mL streptomycin at
37 °C in a 5% CO2 incubator.
A total of 51 frozen gliomas tissues were obtained from
Qilu Hospital of Shandong University. The diagnosis and
classification were based on histological examination
according to the WHO criteria. Written informed consent
was obtained from all patients. The experimental proto-
cols were approved by the Ethics Committee of Qilu
Hospital of Shandong University. All experiments comply
with the laws in China.
Quantitative real-time PCR (qRT-PCR)
Total RNA from tissues or cell lines were extracted
using Trizol (Invitrogen, USA) and treated with RNase-
free DNase (Promega, USA). About 2 μg total RNA was
used to synthesize cDNA with first strand cDNA synthe-
sis kit (Fermentas, USA). Then, qRT-PCR analysis was
performed on the Applied Biosystems 7500 Fast Real-
Time PCR system and software according to the manu-
facturer’s protocol. Relative expression (RE) of RBM5
was calculated with the listed formula:
RE ¼ 2− ΔCt sampleð Þ ‐ ΔCt controlð Þf g
where ΔCt = Ct (RBM5) − Ct (GAPDH). All samples
were repeated in triplicates.
Production of lentivirus and infection of cell lines
pLVX-Puro plasmid was used to express RBM5
(NM_005778.3). The coding sequence of RBM5 was
cloned into empty pLVX-Puro. Then, modified plas-
mid were co-transfected into 293 T cells with lentiviral
packaging plasmids to generate lentivirus vector ex-
pressing RBM5. About 5 × 105 glioma cells/well were
plated in six-well plates and treated with lentivirus
vector at mol 10 when cells grown to 40% confluence.
After infection for 72 h, the expression efficiency of
RBM5 was determined with qRT-PCR or western blot
analysis.
MTT proliferation assay
Gliomas cells expressing RBM5 were seeded into a 96-well
plate at 3 × 103cells/well in 100 μl DMEM (Gibco, USA).
About 20 μl of MTT solution (Sigma, 5 mg/ml) was added
into each well for 5 days, and plates were incubated for
another 4 h at 37 °C before. Then, 200 μl of dimethyl
sulfoxide (DMSO; Sigma) was added to dissolve the
crystals. Absorbance values (A) at 490 nm were measured
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on a microplate reader. Each experiment was repeated in
triplicates.
BrdU incorporation assay
DNA synthesis in gliomas cells was detected by BrdU
incorporation rate. About 5000 cells were seeded into a
96-well plate and incubated for 24 or 48 h. Ten microli-
ters 1 × BrdU were added to the plate from 2 to 24 h
followed by adding 100 μl fixing solution for 30 min.
Then, cells were washed with wash buffer and incubated
with 50 μl 1 × BrdU antibody for 1 h followed by adding
of 50 μl 1 × goat anti-mouse IgG, 50 μl TMB substrate
solution sequentially. After incubation for 30 min, stop
solution was added and absorbance value at 450 nm was
measured on a plate reader.
Transwell assay
The invasive ability of cell lines was analyzed by trans-
well assay using a transwell chamber with or without a
Matrigel-coated filer. About 5 × 105 cells were seeded
into the upper chamber with serum-free medium while
DMEM with 20% FBS was added into the lower cham-
ber. After incubation for 24 h, cells on the upper surface
of the filter were removed and the cells on the lower
surface were stained with crystal violet. The number of
transferred cells was determined by in five random se-
lected fields per well.
Apoptosis assay
About 1 × 106 cells were centrifuged for 5 min at
1500 rpm, washed with cold Biolegend’s Cell Staining
Buffer buffer, and resuspended in Annexin V Binding
Buffer. About 100 μL of cell suspension was transferred
into a 5-ml test tube followed by adding of 5 μL of FITC
Annexin V and 5 μL of 7-ADD Viability Staining
Solution. Gently vortex the cells and incubated at 25 °C
in the dark for 15 min, the volume was raised to 500 μL
with Annexin V Buffer and analyzed on FACSCanto II
Flow cytometry b (BD Biosciences, USA).
Western blot analysis
Cells infected with lenti-RBM5 were seeded into six-well
plates, and total protein was extracted after 72 h with
CelLytic™ MEM Protein Extraction Kit (Sigma-Aldrich,
USA) followed by quantified with bicinchoninic acid assay
(BCA Protein Assay Kit, Generay, Shanghai, China). Then,
5 μg total protein were separated on SDS-polyacrylamide
gel, transferred to nitrocellulose membranes, and incubated
overnight with primary antibodies against Bcl-2, Bax, β-
catenin, cyclin D1 (Santa Cruz Biotechnology, USA) and
TCF, DKK1, GAPDH, Caspase-3, TNF-α (Abcam, USA) at
4 °C. After that, membranes were washed and incubated in
horseradish peroxidase-conjugated secondary antibody for
about 1 h at room temperature and target protein were
determined with ECL kit (Pierce, USA).
Statistical analysis
All data were analyzed by a two-tailed Student’s t test
for statistical difference with SPSS16.0 based on three
independent experiments. The correlation of RBM5 with
clinicopathological factors was analyzed by chi-square
est. Survival curves were plotted by Kaplan-Meier method
and compared by log-rank test. P < 0.05 was recorded as
significant difference.
Results
RBM5 was downregulated in gliomas tissues and
correlated with a poor prognosis
To investigate the clinical significance of RBM5 in gli-
omas, the mRNA level of RBM5 in tumor tissues from 51
patients diagnosed with gliomas and in gliomas cell lines
were detected by qRT-PCR assay. It was shown that
RBM5 was dramatically reduced in tumor tissues com-
pared to paratumor tissues (Fig. 1a). Also, RBM5 was
expressed weakly in three gliomas cells including U87,
U251, and SHG44 (Fig. 1b). Then, clinicopathological ana-
lysis indicated that downregulated RBM5 was significantly
correlated with tumor stage (P = 0.004) but not with age
(P = 0.068) or sex (P = 0.405) (Table 1). Moreover, weak
RBM5 expression was demonstrated to be associated with
poor prognosis. The estimated 5-year survival rate in
patients with low RBM5 expression was about 40.5%
(n = 39), but it was 63.4% in those with high RBM5
expression (n = 19). There was a significant difference be-
tween these two groups (P = 0.018) (Fig. 1c). Our data indi-
cate that RBM5 may function as a suppressor in gliomas.
RBM5 significantly suppressed growth of human gliomas
cells in vitro
To examine the role of RBM5 in gliomas, RBM5 was
overexpressed in U251 and SHG44 cells by lentivirus in-
fection. As shown in Fig. 2, both mRNA and protein
level of RBM5 was successfully upregulated in U251 and
SHG44 cells compared to the parent cells after lentivirus
infection for 96 h. Then, MTT assay and BrdU incorpor-
ation assay were employed to determine cell growth rate.
It was demonstrated that RBM5 overexpression remark-
ably reduced the proliferation of both U251 and SHG44
cells (Fig. 3a, c). The proliferation rate at the fifth day
was only 22.7% in U251 cells and 30.4% in SHG44 cells
compared to the control cells. Similar results were
obtained in BrdU incorporation assay in which U251-
RBM5/OE cells showed a reduction of 37% BrdU
incorporation rate at 24 h and 57% at 72 h (Fig. 3b, d).
So, it was conceived that RBM5 potentially delayed
the growth of gliomas cells and inhibited the DNA
synthesis.
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RBM5 disrupted the migration and invasive ability of
human gliomas cells
RBM5 was reported to be associated with tumor metasta-
sis [15]. Cell migration and invasion were essential for
tumor metastasis. Accordingly, we determined the effect
of RBM5 overexpression on migration and invasiveness of
gliomas cells. In the transwell assay without Matrigel, we
found that RBM5 overexpression significantly blocked the
migration of SHG44 cells (Fig. 4a, b). The cells migrated
through the filter in RBM5 overexpressed group was
about 55% of that in control group. The invasive capacity
was also disrupted in RBM5 overexpressed cells. In the
transwell assay with Matrigel, the cells transferred through
the filter monolayer in SHG44-RBM5/OE (RBM5 overex-
pression) cells were fewer than 40% of that in control
group. To certain extent, the migration of cells may be
influenced by cell proliferation. But on the whole, our data
suggested that RBM5 suppressed both migration and inva-
sion of human gliomas cells.
RBM5 suppressed the Wnt/β-catenin signaling and
induced cell apoptosis
RBM5 was most frequently reported to induce apoptosis
and cell G1/S arrest [12]. Also, it was shown to inhibit
canonical Wnt/β-catenin signaling [14]. So, we determined
the critical molecules in both apoptosis and Wnt/β-catenin
signaling pathway. In consistent with the previous report,
Wnt/β-catenin signaling was blocked by RBM5. The typical
molecules including β-catenin and Cyclin D1 were signifi-
cantly decreased in SHG44-RBM5/OE cells. On contrary,
P-GSK-3β and DKK1 levels were increased (Fig. 5a). Mean-
while, the apoptosis signaling was activated by RBM5. As
shown in Fig. 5a, Bcl-2 expression was reduced greatly
while pro-apoptotic molecules including Bax, TNF-α, and
cleaved caspase3 were upregulated remarkably in SHG44-
Fig. 1 RBM5 was downregulated in gliomas and associated with prognosis of gliomas patients. The expression of RBM5 was detected in 51 gliomas
tissues and 3 cell lines by RT-qPCR. Then, the relationship of RBM5 level with survival time was analyzed by Kaplan-Meier method and compared by
log-rank test. a RT-qPCR analysis of RBM5 mRNA in tumor tissues. b RT-qPCR analysis of RBM5 mRNA in cell lines U87, U251, and SHG44.
c The correlation analysis of RBM5 expression with 5-year survival time in gliomas patients. Data were shown as means ± SD of three
independent experiments. *P < 0.05 was considered as statistically significant
Table 1 RBM5 expression was correlated with clinicopathological
characteristics of gliomas
Characteristics Total RBM5 expression P value
Low High
All cases 51 28 23
Age (year) 0.068
<60 22 13 9
≥60 29 15 14
Grade 21 9 12 0.148
G1/G2 21 9 12
G3/G4 30 19 11
TNM stage 0.004
Early (I/II) 23 8 17
Late (III/IV) 28 20 8
Sex 0.405
Male 32 19 13
Female 19 9 10
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RBM5/OE cells. And the apoptotic rate in SHG44-RBM5/
OE cells increased greatly compared to the control (from 0
to 32%). So, our data suggest that RBM5 could simultan-
eously inhibit Wnt/β-catenin signaling and activate apop-
tosis in human gliomas cells.
Discussions
Gliomas, one of the most common malignant brain tumors,
showed increasing morbidity and mortality in recent years.
But regardless of the unsatisfactory prognosis of gliomas,
elucidation of implicit molecular mechanism have enriched
our knowledge about tumor and pushed forward the war
against tumor. Of the reported critical genes in tumors,
RBM5 was a tumor suppressor and enhanced tumor cell
apoptosis in a list of tumors. Peng et al. demonstrated that
RBM5 underexpression was closely correlated with poor
clinicopathological features in pancreatic cancer [16]. Con-
sistently, RBM5 was shown to be weakly expressed in either
gliomas tissues or cell lines here. And RBM5 expression
was clinically correlated with tumor stage but not sex. This
was inconsistent with the previous study in which gliomas
incidence was reported higher in male patients than that in
female patients aged between 30 and 40 years [17]. Maybe
a larger cohort of gliomas patients is necessary to support
this conclusion. In addition, patient with low RBM5 expres-
sion showed worse prognosis than those with high RBM5
expression. These data pointed out the clinical value of
RBM5 in gliomas.
To investigate the role of RBM5 in gliomas, we success-
fully constructed a gliomas cell line stably expressing
RBM5 with lentivirus vector. Our data demonstrated that
upregulated RBM5 significantly inhibited cell growth and
disrupted DNA synthesis in gliomas cells. DNA synthesis is
a critical process in cell cycle and keeps the maintenance of
genetic information during mitosis which is ensued by
proliferation. Further, both migration ability and invasive
capacity of gliomas cells were markedly suppressed by
RBM5 overexpression. Migration and invasiveness generally
precede metastasis during tumor progression. And it is
known that tumors are characterized by uncontrolled cell
proliferation and potent aggressive ability [18]. Based on
these facts, we concluded that RBM5 played a suppressor
role in gliomas.
But how did RBM5 suppress oncogenesis and metastasis
in gliomas? The first as well as the most reported
mechanism was that RBM5 could activate apoptotic
signaling and enhance cell apoptosis [12]. Apoptosis,
also called programmed cell death (PCD), was a com-
plex activity involving multiple genes and was vital to
the physiological and pathological process of cell life.
Bcl-2 and Bax, often form heterodimers, are two most
important regulators in apoptotic signaling pathway
Fig. 2 RBM5 was successfully overexpressed in U251 and SHG44 cells. RBM5 was introduced into U251 and SHG44 cells by lentivirus and confirmed
by RT-qPCR and western blot analysis. a RT-qPCR analysis of RBM5 mRNA in U251 cells. b RT-qPCR analysis of RBM5 mRNA in SHG44 cells. c Western
blot analysis of RBM5 protein in U251 and SHG44 cells. Data were shown as means ± SD of three independent experiments. *P < 0.05 was considered
as statistically significant
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[12]. They are reversely correlated during PCD process
which means that Bcl-2 antagonizes the effect of Bax
and vice verse. Caspase cascade response directly
caused cell PCD, and this process includes sequentially
activation of key effectors such as caspase-9 and
caspase-3. In lung cancer cells transfected with RBM5,
pro-apoptotic protein Bax was increased while anti-
apoptotic protein Bcl-2 was decreased reversely [12].
Meanwhile, mitochondrial apoptotic pathway was also
activated by RBM5 as caspase-9 and caspase-3 activity
Fig. 4 RBM5 disrupted migration and invasive ability in gliomas cells. Cells were seeded into the upper chamber, and the migrated or invasive
ability was observed at 24 h in a transwell assay with/without Matrigel. a Migration of SHG44 cells was blocked when invasive cells were reduced
by RBM5. b The migrate rate of SHG44 cells in a transwell assay without Matrigel. c The invaded SHG44 cells in a transwell assay with Matrigel.
Each experiment was repeated in triplicates. *P < 0.05 was considered as statistically significant
Fig. 3 RBM5 inhibited proliferation and DNA synthesis in gliomas cells. Cells expressing RBM5 were seeded into 96-well plates and were counted
for consecutive 5 days. To determine DNA synthesis, BrdU was added 2 h after cells were cultured and absorbance value at 450 nm was detected
at 24 and 72 h, respectively. a The growth of U251 cells overexpressing RBM5. b DNA synthesis in U251 cells overexpressing RBM5. c The growth
of SHG44 cells overexpressing RBM5. d DNA synthesis in SHG44 cells overexpressing RBM5. Each experiment was repeated in triplicates. *P < 0.05
was considered as statistically significant
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was upregulated greatly. In another study, expression
of cleaved caspase-9 and cleaved caspase-3 was upregulated
by RBM5 in prostate cancer [10]. In this study, we demon-
strated that Bcl-2 was downregulated while the level of Bax,
cleaved caspase-3, and TNF-α was increased significantly
by RBM5 in gliomas cells, which suggest that RBM5, at
least partly, promoted cell apoptosis in gliomas cells. And
apoptosis assay further confirmed the apoptosis-inducing
function of RBM5. The second mechanism of RBM5
involves its anti-proliferative effect and cell cycle arrest.
RBM5 was reported to inhibit cell growth and colony for-
mation through increased p53 in H1299 cells while caused
cell cycle arrest at G1 phase [19]. At the same time, RBM5
was shown to antagonistically regulate the proliferative abil-
ity of cancer cells through alternative splicing of NUMB
gene [8]. However, different with the early reports, we
found in this study that Wnt/β-catenin signaling was acti-
vated by RBM5 in gliomas cells. Wnt/β-catenin signaling
was one typical proliferation-promoting signaling pathway
and has been shown to be activated in various kinds of
tumors. Besides the above two mechanisms, other signaling
may be also involved in the anti-tumor role of RBM5. For
example, RBM5 was also shown to downregulate EGFR
expression and induce cell autophagy [20, 21]. Autophagy
is another autonomic programmed cell death or type II
PCD. But its role in gliomas needs more study. Accord-
ingly, our data proved that RBM5 promoted tumorigenesis
of gliomas through activation of Wnt/β-catenin signaling
and increased cell apoptosis.
Conclusions
In summary, RBM5 was downregulated in gliomas and dis-
rupted both proliferation and migration ability of gliomas
cells by activating Wnt/β-catenin signaling and inducing
cell apoptosis. Our data suggest that RBM5 plays a suppres-
sor role in gliomas and provide a new promising thera-
peutic target for patients with gliomas.
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